More Stories

Informist, Monday, Aug. 10, 2026

By Narayana Krishna and Gunjan Rajput

HYDERABAD/NEW DELHI – Gland Pharma Ltd. on Monday said contract development and manufacturing organisation business will remain a key pillar to drive the company's growth going forward. With robust order books and execution, this segment will contribute around 50% of the total revenue for the next few years, Srinvas Sadu, executive chairman, said in the company's post-earnings conference call with analysts.

The company reported a consolidated net profit of INR 3.17 billion for the June quarter, up 47% on year but down over 13% on quarter. Revenue from operations for the quarter was up nearly 20% on year and 3% on quarter at INR 18 billion. Contract development and manufacturing organisation operations contributed INR 8.9 billion to the overall revenue with a 20% year-on-year and 11% quarter-on-quarter growth.

Sadu said the integration of its acquired French company Cenexi was fully completed, with the CDMO business and modernisation of facilities in progress. 

"Our CDMO business continues to deliver strong growth during the quarter and remains one of the key pillars of our long-term strategy...Our customer engagement remains strong and we continue to attract robust global pharmaceutical companies seeking reliability to our manufacturing partners. Our pipeline of development and commercial opportunities remains healthy and provides good visibility for future growth," Sadu said.

Explaining the details of its latest contract manufacturing deal with a global pharmaceutical company, Sadu said the contract is to make oncology and non-oncology products. The client is a globally known specialty pharma company, and the technology transfer of the products that are set to be manufactured by Gland Pharma will begin from September, he said. The tech transfer and other regulatory processes will take at least two years, and the actual revenue is expected to begin in 2029, he said. The company will manufacture all the products under this pact in its facilities in India, though a small portion may be made by Cenexi, he said.

"And the first set of products will be transferred in 24 months. Every quarter we'll be filing certain products. So 50% of the products are for the US market, and 30-35% for the European market and the rest for the world market," he said.

Sadu said the company has recently signed a manufacturing contract with a client to make glucagon-like-peptide-1 category products such as semaglutide and tirzepatide. The company is expecting technology transfer of these products in the next one or two quarters, and the products are for the US and Europe markets, he said. The company is expecting limited contribution from GLP-1 category products over the next three years.

As the company's certain business are running at full capacity, Gland Pharma is in the process of expanding its capacities by adding more lines along with modernising the facilities. The company is expecting its capital expenditure for the financial year 2026-27(Apr-Mar) around INR 5.5 billion. The company had cash or cash equivalents of INR 35.4 billion as of Jun. 30.

On Monday, shares Gland Pharma closed 2.6% higher at INR 2,667.30 on the National Stock Exchange.  End

Edited by Deepshikha Bhardwaj

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.